Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly CEO weighs in on Q4 revenue miss
09:49am, Thursday, 02'nd Feb 2023
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's change in guidance, the outlook for the company's Diabetes drug, and Eli Lilly's manufacturing capacity of the new drug, Mounjaro.
Eli Lilly (LLY) Q4 Earnings Surpass Estimates
09:47am, Thursday, 02'nd Feb 2023
Lilly (LLY) delivered earnings and revenue surprises of 14.21% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly's stock falls after Q4 revenue miss
07:18am, Thursday, 02'nd Feb 2023
Eli Lilly & Co.'s LLY, -0.46% stock fell 2.3% before market open Thursday after the biopharmaceutical giant's fourth-quarter revenue came in below analysts' expectations. The company reported net inco
Eli Lilly Stock Falls Even as Earnings Crush Estimates
07:03am, Thursday, 02'nd Feb 2023
The pharmaceutical group reports earnings of $2.09 a share in the fourth quarter on revenue of $7.3 billion.
Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock
09:53am, Wednesday, 01'st Feb 2023
Ironically, it was the drug's own effectiveness that led to the FDA not granting approval.
FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld
03:26pm, Friday, 27'th Jan 2023 Zacks Investment Research
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
02:57pm, Friday, 27'th Jan 2023 Zacks Investment Research
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
01:23pm, Friday, 27'th Jan 2023 Zacks Investment Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
01:14pm, Friday, 27'th Jan 2023 Zacks Investment Research
J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
11:50am, Friday, 27'th Jan 2023 The Motley Fool
These companies have the therapies to boost revenue for a decade.
Could This New Drug Indication Be a Winner for Eli Lilly?
03:15pm, Thursday, 26'th Jan 2023 The Motley Fool
The FDA could be just months away from approving Eli Lilly and Boehringer Ingelheim's drug candidate to treat a common condition.
Is It Too Late to Buy Eli Lilly Stock?
02:38pm, Thursday, 26'th Jan 2023 The Motley Fool
At a $325 billion market cap, the business is already huge -- does it have much more room to grow?
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
02:00pm, Thursday, 26'th Jan 2023 Zacks Investment Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Could This New Drug Indication Be a Winner for Eli Lilly?
10:15am, Thursday, 26'th Jan 2023
The FDA could be just months away from approving Eli Lilly and Boehringer Ingelheim's drug candidate to treat a common condition.
Is It Too Late to Buy Eli Lilly Stock?
09:38am, Thursday, 26'th Jan 2023
At a $325 billion market cap, the business is already huge -- does it have much more room to grow?
